Quanterix (QTRX) Competitors

$2.64 +0.12 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$2.66 +0.02 (+0.76%)

As of 04:10 PM Eastern

QTRX vs. SIBN, CTKB, LAB, NAUT, and OPTX

Should you buy Quanterix stock or one of its competitors? MarketBeat compares Quanterix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quanterix include SiBone (SIBN), Cytek Biosciences (CTKB), Standard BioTools (LAB), Nautilus Biotechnology (NAUT), and Syntec Optics (OPTX).

How does Quanterix compare to SiBone?

SiBone (NASDAQ:SIBN) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, SiBone had 4 more articles in the media than Quanterix. MarketBeat recorded 4 mentions for SiBone and 0 mentions for Quanterix. SiBone's average media sentiment score of 0.11 beat Quanterix's score of 0.00 indicating that SiBone is being referred to more favorably in the media.

Company	Overall Sentiment
SiBone	Neutral
Quanterix	Neutral

98.1% of SiBone shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

SiBone presently has a consensus price target of $23.00, suggesting a potential upside of 55.30%. Quanterix has a consensus price target of $4.00, suggesting a potential upside of 51.52%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

SiBone has a net margin of -8.10% compared to Quanterix's net margin of -71.86%. SiBone's return on equity of -9.56% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Quanterix	-71.86%	-23.92%	-17.66%

SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.27	-$18.90M	-$0.39	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.36	N/A

Summary

SiBone beats Quanterix on 14 of the 16 factors compared between the two stocks.

How does Quanterix compare to Cytek Biosciences?

Quanterix (NASDAQ:QTRX) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Quanterix currently has a consensus target price of $4.00, suggesting a potential upside of 51.52%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 43.62%. Given Quanterix's higher probable upside, equities analysts plainly believe Quanterix is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cytek Biosciences has higher revenue and earnings than Quanterix. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.90	-$107.15M	-$2.36	N/A
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A

In the previous week, Cytek Biosciences had 1 more articles in the media than Quanterix. MarketBeat recorded 1 mentions for Cytek Biosciences and 0 mentions for Quanterix. Quanterix's average media sentiment score of 0.00 equaled Cytek Biosciences'average media sentiment score.

Company	Overall Sentiment
Quanterix	Neutral
Cytek Biosciences	Neutral

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytek Biosciences has a net margin of -36.25% compared to Quanterix's net margin of -71.86%. Cytek Biosciences' return on equity of -10.07% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Quanterix has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Summary

Cytek Biosciences beats Quanterix on 12 of the 15 factors compared between the two stocks.

How does Quanterix compare to Standard BioTools?

Quanterix (NASDAQ:QTRX) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Standard BioTools had 1 more articles in the media than Quanterix. MarketBeat recorded 1 mentions for Standard BioTools and 0 mentions for Quanterix. Quanterix's average media sentiment score of 0.00 equaled Standard BioTools'average media sentiment score.

Company	Overall Sentiment
Quanterix	Neutral
Standard BioTools	Neutral

Quanterix has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Quanterix presently has a consensus target price of $4.00, indicating a potential upside of 51.52%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 29.81%. Given Quanterix's higher probable upside, equities analysts clearly believe Quanterix is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has a net margin of 73.46% compared to Quanterix's net margin of -71.86%. Standard BioTools' return on equity of -8.18% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
Standard BioTools	73.46%	-8.18%	-6.43%

Standard BioTools has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	0.90	-$107.15M	-$2.36	N/A
Standard BioTools	$85.33M	4.76	-$74.90M	$0.20	5.20

86.5% of Quanterix shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Standard BioTools beats Quanterix on 10 of the 13 factors compared between the two stocks.

How does Quanterix compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Nautilus Biotechnology had 1 more articles in the media than Quanterix. MarketBeat recorded 1 mentions for Nautilus Biotechnology and 0 mentions for Quanterix. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Quanterix'saverage media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Quanterix	Neutral

Nautilus Biotechnology has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Nautilus Biotechnology has higher earnings, but lower revenue than Quanterix. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.36	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Quanterix's net margin of -71.86%. Quanterix's return on equity of -23.92% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Quanterix	-71.86%	-23.92%	-17.66%

Nautilus Biotechnology currently has a consensus price target of $4.00, indicating a potential upside of 57.48%. Quanterix has a consensus price target of $4.00, indicating a potential upside of 51.52%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Nautilus Biotechnology beats Quanterix on 8 of the 14 factors compared between the two stocks.

How does Quanterix compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Quanterix (NASDAQ:QTRX) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Quanterix has a consensus target price of $4.00, suggesting a potential upside of 51.52%. Given Quanterix's stronger consensus rating and higher possible upside, analysts clearly believe Quanterix is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Syntec Optics has higher earnings, but lower revenue than Quanterix. Syntec Optics is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$27.53M	14.70	-$1.79M	-$0.08	N/A
Quanterix	$138.90M	0.90	-$107.15M	-$2.36	N/A

Syntec Optics has a net margin of -10.95% compared to Quanterix's net margin of -71.86%. Quanterix's return on equity of -23.92% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Quanterix	-71.86%	-23.92%	-17.66%

Syntec Optics has a beta of -0.93, meaning that its stock price is 193% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, Syntec Optics had 7 more articles in the media than Quanterix. MarketBeat recorded 7 mentions for Syntec Optics and 0 mentions for Quanterix. Syntec Optics' average media sentiment score of 0.43 beat Quanterix's score of 0.00 indicating that Syntec Optics is being referred to more favorably in the media.

Company	Overall Sentiment
Syntec Optics	Neutral
Quanterix	Neutral

86.5% of Quanterix shares are held by institutional investors. 0.8% of Syntec Optics shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Quanterix beats Syntec Optics on 8 of the 15 factors compared between the two stocks.

Get Quanterix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTRX vs. The Competition

Export

Metric	Quanterix	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$124.37M	$8.29B	$6.34B	$12.29B
Dividend Yield	N/A	2.52%	2.80%	5.36%
P/E Ratio	-1.12	16.25	20.94	25.48
Price / Sales	0.90	8.54	521.14	73.34
Price / Cash	N/A	16.94	43.18	55.00
Price / Book	0.44	4.05	9.98	7.00
Net Income	-$107.15M	$224.05M	$3.55B	$335.16M
7 Day Performance	-4.69%	2.91%	0.42%	-0.29%
1 Month Performance	-18.01%	4.77%	-0.05%	1.15%
1 Year Performance	-45.11%	2.13%	35.06%	34.79%

Quanterix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTRX Quanterix	1.715 of 5 stars	$2.64 +4.8%	$4.00 +51.5%	-49.5%	$124.37M	$138.90M	N/A	460
SIBN SiBone	2.6068 of 5 stars	$14.76 +4.2%	$23.00 +55.8%	-24.8%	$627.99M	$200.93M	N/A	350	Insider Trade
CTKB Cytek Biosciences	1.7295 of 5 stars	$3.55 +4.4%	$5.69 +60.2%	+41.7%	$439.73M	$204.17M	N/A	500
LAB Standard BioTools	2.2497 of 5 stars	$0.99 +0.4%	$1.35 +36.5%	+1.0%	$384.43M	$86.26M	4.95	620	Positive News
NAUT Nautilus Biotechnology	2.7856 of 5 stars	$2.36 -6.0%	$4.00 +69.5%	+189.5%	$318.97M	N/A	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTRX) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quanterix (QTRX) Competitors

QTRX vs. SIBN, CTKB, LAB, NAUT, and OPTX

How does Quanterix compare to SiBone?

Summary

How does Quanterix compare to Cytek Biosciences?

Summary

How does Quanterix compare to Standard BioTools?

Summary

How does Quanterix compare to Nautilus Biotechnology?

Summary

How does Quanterix compare to Syntec Optics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quanterix (QTRX) Competitors

QTRX vs. SIBN, CTKB, LAB, NAUT, and OPTX

How does Quanterix compare to SiBone?

Does the media prefer SIBN or QTRX?

Do insiders and institutionals have more ownership in SIBN or QTRX?

Do analysts recommend SIBN or QTRX?

Is SIBN or QTRX more profitable?

Which has more risk and volatility, SIBN or QTRX?

Which has better earnings and valuation, SIBN or QTRX?

Summary

How does Quanterix compare to Cytek Biosciences?

Do analysts recommend QTRX or CTKB?

Which has higher valuation and earnings, QTRX or CTKB?

Does the media favor QTRX or CTKB?

Do institutionals & insiders have more ownership in QTRX or CTKB?

Is QTRX or CTKB more profitable?

Which has more volatility and risk, QTRX or CTKB?

Summary

How does Quanterix compare to Standard BioTools?

Does the media favor QTRX or LAB?

Which has more risk & volatility, QTRX or LAB?

Do analysts recommend QTRX or LAB?

Is QTRX or LAB more profitable?

Which has preferable earnings and valuation, QTRX or LAB?

Do insiders & institutionals believe in QTRX or LAB?

Summary

How does Quanterix compare to Nautilus Biotechnology?

Do insiders and institutionals believe in NAUT or QTRX?

Does the media prefer NAUT or QTRX?

Which has more volatility and risk, NAUT or QTRX?

Which has preferable earnings & valuation, NAUT or QTRX?

Is NAUT or QTRX more profitable?

Do analysts rate NAUT or QTRX?

Summary

How does Quanterix compare to Syntec Optics?

Do analysts rate OPTX or QTRX?

Which has stronger valuation and earnings, OPTX or QTRX?

Is OPTX or QTRX more profitable?

Which has more risk & volatility, OPTX or QTRX?

Does the media prefer OPTX or QTRX?

Do institutionals & insiders have more ownership in OPTX or QTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools